Capsular polysaccharide of Streptococcus pneumoniae serotype 6B (CPS 6B)

The capsular polysaccharide of Streptococcus pneumoniae serotype 6B is a complex carbohydrate polymer that forms the outermost layer of the bacterium. It serves as a critical virulence factor by shielding the pathogen from the host's immune system, primarily by preventing complement deposition and subsequent phagocytosis by neutrophils and macrophages (Source: PubMed, PMID: 11854167). Serotype 6B is historically one of the most common causes of invasive pneumococcal disease (IPD) and antibiotic resistance worldwide, particularly in pediatric populations (Source: CDC). As a therapeutic target, this polysaccharide is utilized as an antigen in both conjugate and unconjugated pneumococcal vaccines, such as Prevnar 13 and Pneumovax 23 (Source: FDA). When administered, it induces the production of serotype-specific antibodies that provide protective immunity against infections such as pneumonia, meningitis, and bacteremia. Modern conjugate vaccines link this polysaccharide to a carrier protein, such as CRM197, to enhance the T-cell dependent immune response, which is vital for efficacy in infants and the elderly (Source: WHO). The chemical structure of the 6B polysaccharide consists of a repeating unit of galactose, glucose, rhamnose, and ribitol phosphate (Source: PubChem). Targeting this molecule has significantly reduced the global burden of pneumococcal disease, although it necessitates ongoing epidemiological monitoring for serotype replacement (Source: Lancet Infectious Diseases).

Other names

Pneumococcal polysaccharide serotype 6BStreptococcus pneumoniae serotype 6B capsular polysaccharideCPS6BSerotype 6B capsular antigen

Induction of a serotype-specific humoral immune response, characterized by the production of opsonizing IgG antibodies that facilitate the phagocytosis and clearance of the bacteria by host immune cells (Source: CDC, Pink Book).